TRACON Announces Clinical Data Presentations at Upcoming

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
158
TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting

SAN DIEGO, May 25, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for its two most advanced clinical stage oncology product candidates, TRC105 and TRC102, at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held June 2-6, 2017, in Chicago, Illinois.

The following is a summary of the four presentations that will be given at ASCO:

Poster Discussion Presentations
 
Title:   A Phase I Trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients 
  with solid tumors and lymphomas ( Abstract #2518 )
Presenter: Robert S. Meehan, MD, National Cancer Institute
Location: S Hall A, Poster Board 10 (poster display)
  Arie Crown Theater (poster discussion)
Date/Time: Monday, June 5, 2017, 8:00 AM – 11:30 AM, Central time (poster display)
  Monday, June 5, 2017, 11:30 AM – 12:45 PM, Central time (poster discussion)
   
Title:   NCCTG N1174: Phase I/comparative randomized Phase II trial of TRC105 plus 
  bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) ( Abstract #2023 )
Presenter: Evanthia Galanis, MD, Mayo Clinic
Location: S Hall A, Poster Board 265 (poster display)
  S404 (poster discussion)
Date/Time: Monday, June 5, 2017, 1:15 PM – 4:45 PM, Central time (poster display)
  Monday, June 5, 2017, 4:45 PM – 6:00 PM, Central time (poster discussion)
 
General Poster Presentations
 
Title:   Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF
  therapy ( Abstract #11546 )
Presenter: Yingmiao Liu, Ph.D., Duke University Medical Center
Location: S Hall A, Poster Board 246
Date/Time: Saturday, June 3, 2017, 1:15 PM – 4:45 PM, Central time
   
Title:   TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus 
  pazopanib alone in patients with advanced angiosarcoma ( Abstract #TPS11081 )
Presenter: Robin Lewis Jones, BSc, MB, MRCP, MD, Royal Marsden Hospital
Location: S Hall A, Poster Board 403a
Date/Time: Sunday, June 4, 2017, 8:00 AM – 11:30 AM, Central time

About Carotuximab ( TRC105 )  

TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in one Phase 3 and multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumors in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php .

About TRC102  

TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php .

About TRACON  

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com .

Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 clogan@traconpharma.com Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

K-Jeonnam Gim Debuts on Amazon: Korean Seaweed Arrives

Updated Category News Views 114

Korean Seaweed Ventures to the US Market Alright, folks, here's a twist for your snack drawer—Korean seaweed making waves right on Amazon's virtual shelves! Shinan 1004 Seaweed Co. is shaking things up with their brand spankin' new K-Jeonnam Gim. This ain't just any old sea greens we're talking about. We're dealing with crispy, roasted sheets bursting with savory, nutty...

Continue Reading
Surfshark's No-Logs Policy Gets KPMG Backing

Updated Category News Views 168

Surfshark's Commitment to Privacy Pardon my grizzled voice, but in today's world, where digital privacy often feels like a myth, having a VPN that sticks to its guns about not keeping logs is rare enough to make you look twice. Well, here comes Surfshark, loudly touting yet another seal of approval from one of the Big Four—KPMG. Not the first time for these folks, but...

Continue Reading
Finding the Right Auto Insurance: What to Consider

Updated Category News Views 188

Understanding the Basics of Auto Insurance Coverage Now, you might think the state knows best when it sets those minimum auto insurance requirements. But let's not kid ourselves—skimping on coverage can leave you high and dry if things go south on the road. That's where an expert voice like Corey Frazer's comes in, laying out why those limits often fall short. Minimum...

Continue Reading
Schools Reimagine Yearbooks with Interactive Archives

Updated Category News Views 80

Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...

Continue Reading
Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 58

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
$10,000 Boost Fuels Nichols College's Archaeological Quest

Updated Category News Views 178

Webster First's Generous Contribution It's not every day you see a credit union digging into history—literally. Webster First Federal Credit Union just dropped ten grand to fuel Nichols College's archaeological adventures. This isn't some trivial check to post on Instagram. No, we're talking about funding some serious ground-penetrating radar (GPR) gadgetry that's set...

Continue Reading
Noël Jolié's Cream Earns Spot on Oprah's List

Updated Category News Views 98

The Powerhouse of Oprah's Seal of Approval Ever notice what happens when Oprah drops a nod towards any brand? It's like Midas touching everything gold. That's exactly the scenario with Noël Jolié, a Chicago-based luxury body care operation, hitting the jackpot by landing its Velours Silken Body Cream on Oprah's Favorite Things 2026. You can't buy this kind of press,...

Continue Reading
BULL Faces Class Action After Regulatory Fines

Updated Category News Views 109

Webull's Financial Quake Shakes Investors You don't expect to wake up to news of a stock in freefall, but here we are with Webull (NASDAQ:BULL) cratering after some rough compliance problems came to light. On November 5, 2026, Webull's stock tumbled nearly 11% thanks to FINRA slapping them with a $4.2 million fine for failing to keep their anti-money laundering (AML) and...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Innovative Rotating Kitchen Organizer Up for Licensing

Updated Category News Views 87

Dusting Off the Corners: A Fresh Spin on Kitchen Storage Just when you think there's nothing new under the sun when it comes to storing your kitchen gadgets, here comes an invention straight out of Billings, Montana. It's called The Rotating Kitchen Organizer, a nifty contraption that's all set to turn those dead corners into prime real estate. How many times have we...

Continue Reading

Top 5 Most Recently Viewed Articles

Sital K. Mody Joins First Horizon's Board of Directors

Updated Category News Views 418

First Horizon Welcomes Sital K. Mody to Its Board First Horizon Corporation (NYSE: FHN) is excited to announce the election of Sital K. Mody as an independent director to its Board of Directors and First Horizon Bank Board. With a wealth of experience in the energy sector and a deep understanding of operational excellence, Mody is expected to contribute significantly to...

Continue Reading
Sky Labs' Apollon Device Achieves CES 2025 Innovation Honor

Updated Category News Views 298

Sky Labs Receives CES 2025 Innovation Award for Apollon Sky Labs recently made headlines with their innovative wearable technology, the Apollon device, which has been recognized as an Honoree in the Artificial Intelligence category at the prestigious CES 2025 Innovation Awards. This honor is awarded by the Consumer Technology Association (CTA) and signifies the remarkable...

Continue Reading
Navigating the Markets: Insights on Key Investments

Updated Category News Views 137

Understanding Market Trends and Key Stocks Good Morning Traders! As we embark on this week, the economic landscape presents a rather light start. Although the calendar is not burdened with high-impact data initially, the market holds potential for movement as we approach critical events. Today, manufacturing data is expected to be released, providing insight into the...

Continue Reading
OPENLANE to Release Earnings Results and Conference Details

Updated Category News Views 134

OPENLANE to Announce Third Quarter Financial Results OPENLANE, Inc. (NYSE: KAR), a prominent platform for digital marketplaces in the wholesale used vehicle sector, is set to unveil its financial results for the third quarter of 2025. This announcement is scheduled to occur before market hours on a Wednesday in early November. Conference Call and Webcast Information In...

Continue Reading
Kempinski Hotels and BTG Hotels Unite to Enhance Luxury Travel

Updated Category News Views 230

Kempinski Hotels and BTG Hotels Collaboration Kempinski Hotels is excited to announce an extended strategic partnership with BTG Hotels, highlighting their dedication to luxury hospitality in China. For over 30 years, both companies have played significant roles in shaping the luxury hotel landscape, and this new chapter promises to solidify their status further. Goals of...

Continue Reading